Weber, M. S., Prod’homme, T., Youssef, S., Dunn, S. E., Steinman, L., & Zamvil, S. S. (2014). Neither T-helper type 2 nor Foxp3(+) regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. BioMed Central.
Citación estilo ChicagoWeber, Martin S., Thomas Prod’homme, Sawsan Youssef, Shannon E. Dunn, Lawrence Steinman, y Scott S. Zamvil. Neither T-helper Type 2 nor Foxp3(+) Regulatory T Cells Are Necessary for Therapeutic Benefit of Atorvastatin in Treatment of Central Nervous System Autoimmunity. BioMed Central, 2014.
Cita MLAWeber, Martin S., et al. Neither T-helper Type 2 nor Foxp3(+) Regulatory T Cells Are Necessary for Therapeutic Benefit of Atorvastatin in Treatment of Central Nervous System Autoimmunity. BioMed Central, 2014.